{
  "index": 282,
  "prompt": "\nGiven the following scenario, first consider the actors and stakeholders involved then extrapolate and present as a timeline how the situation might evolve. \nConsider as many multiple possibilities based on possible responses which are to be represented as branches on this timeline. \n\nMake sure that the timeline generated are of **HIGH QUALITY** as defined by the following criteria\n* Plausibility: Economic, financial and political plausibility of each path on the timeline \n    * High: Events are strongly supported by current macro data, institutional knowledge, and have strong analogs in history or system models (e.g., “monetary tightening leads to recession, triggering a political backlash”)\n    * Low: Contains major violations of cause-effect logic, timing, or real-world behavior (e.g., hyperinflation causes interest rate cuts during a currency collapse)\n* Novelty: Creativity/originality in the nodes and paths, are they something you may have overlooked?\n    * High: Demonstrates expert-level creative reasoning. Identifies counterintuitive paths, rare risks, or hidden feedback loops. May challenge conventional wisdom in a grounded way (e.g., “trade war accelerates global realignment of semiconductors via Middle East sovereign wealth capital”). Could lead to edge in investment or policy thinking.\n    * Low: Timeline is linear, obvious, or closely tracks past headlines or boilerplate analysis. No creative branching or exploration.\n* Elaboration: How specific and refined are the occurrences represented by the nodes?\n    * High: Timeline reads like a mini-case study. Each node could stand alone as an actionable insight. Paths show feedback loops, strategic responses, and sector-level granularity (e.g., “Volkswagen reallocates $1.2B R&D from EVs to hybrid tech in response to rare earth prices”). Truly investment-grade thinking.\n    * Low: Nodes are generic (e.g., “market reacts”, “tensions rise”) with no detail on mechanisms, actors, or consequences. Lacks causal clarity.\n* Actionable: Can this timeline inform specific investment actions or hedging strategies?\n    * High: Timeline includes sector impacts, asset class consequences, or opportunities (e.g., “short EU auto suppliers”, “long U.S. rail freight”)\n    * Low: Insightful narrative, but no clear link to tradable instruments or positioning ideas\n\nKeep to the output format below where ascii is used to represent the timeline as a tree. \n\n[Example of Scenario]\nWASHINGTON/DETROIT, April 29 (Reuters) - U.S. President Donald Trump signed a pair of orders to soften the blow of his auto tariffs on Tuesday with a mix of credits and relief from other levies on materials, and his trade team touted its first deal with a foreign trading partner.\nThe developments helped eased some investor worries about the erratic trade policies of Trump as the president visited Michigan, a cradle of the U.S. auto industry, just days before a fresh set of 25% import taxes was set to kick in on automotive components.\n\n[Example of Output]\n{\n  \"id\": \"T0\",\n  \"title\": \"Initial Event\",\n  \"description\": \"German inflation data released at 2.2%\",\n  \"children\": [\n    {\n      \"id\": \"T1A1\",\n      \"title\": \"ECB maintains dovish stance\",\n      \"date_range\": \"May\",\n      \"description\": \"ECB maintains dovish stance, keeps rates low\",\n      \"children\": [\n        {\n          \"id\": \"T1A1.1\",\n          \"title\": \"German banks increase lending\",\n          \"description\": \"German banks benefit from low rates, increase lending\"\n        },\n        {\n          \"id\": \"T1A1.2\",\n          \"title\": \"Euro weakens\",\n          \"description\": \"Euro weakens, boosting exports\"\n        },\n        {\n          \"id\": \"T1A1.3\",\n          \"title\": \"Moderate industrial growth\",\n          \"description\": \"German industry reports moderate growth\"\n        },\n        {\n          \"id\": \"T1A1.4\",\n          \"title\": \"Bundesbank caution\",\n          \"description\": \"Bundesbank signals caution on inflation\",\n          \"children\": [\n            {\n              \"id\": \"T2A1\",\n              \"title\": \"Industry adapts to inflation\",\n              \"date_range\": \"June–August\",\n              \"description\": \"Companies pass on higher costs; unions request wage hikes; consumer shifts emerge\",\n              \"children\": [\n                {\n                  \"id\": \"T3A1\",\n                  \"title\": \"Markets stabilize\",\n                  \"date_range\": \"Q3–Q4\",\n                  \"description\": \"Eurozone growth outlook improves; German stocks outperform\",\n                  \"children\": [\n                    {\n                      \"id\": \"T4A1\",\n                      \"title\": \"Global growth stabilizes\",\n                      \"date_range\": \"Q4–2025\",\n                      \"description\": \"Global trade rebounds; emerging markets benefit\",\n                      \"children\": [\n                        {\n                          \"id\": \"T5A1\",\n                          \"title\": \"New normal\",\n                          \"date_range\": \"2025+\",\n                          \"description\": \"Stable growth across EU/US; ECB remains dovish\"\n                        }\n                      ]\n                    }\n                  ]\n                }\n              ]\n            }\n          ]\n        }\n      ]\n    },\n    {\n      \"id\": \"T1A2\",\n      \"title\": \"ECB tightens monetary policy\",\n      \"date_range\": \"May\",\n      \"description\": \"ECB tightens policy in response to inflation\",\n      \"children\": [\n        {\n          \"id\": \"T1A2.1\",\n          \"title\": \"Euro strengthens\",\n          \"description\": \"Euro strengthens, hurting exports\"\n        },\n        {\n          \"id\": \"T1A2.2\",\n          \"title\": \"Industrial slowdown\",\n          \"description\": \"German industry reports slower growth\"\n        },\n        {\n          \"id\": \"T1A2.3\",\n          \"title\": \"Bundesbank warns\",\n          \"description\": \"Bundesbank warns of inflation risks\"\n        },\n        {\n          \"id\": \"T1A2.4\",\n          \"title\": \"Consumers cut back\",\n          \"description\": \"German consumers cut back on spending\",\n          \"children\": [\n            {\n              \"id\": \"T2A2\",\n              \"title\": \"Industry opposes ECB policy\",\n              \"date_range\": \"June–August\",\n              \"description\": \"Job cuts, political backlash, delayed consumption\",\n              \"children\": [\n                {\n                  \"id\": \"T3A2\",\n                  \"title\": \"Markets unstable\",\n                  \"date_range\": \"Q3–Q4\",\n                  \"description\": \"Growth outlook declines; ECB remains hawkish\",\n                  \"children\": [\n                    {\n                      \"id\": \"T4A2\",\n                      \"title\": \"Global recession risk rises\",\n                      \"date_range\": \"Q4–2025\",\n                      \"description\": \"Trade slows; emerging markets struggle\",\n                      \"children\": [\n                        {\n                          \"id\": \"T5A2\",\n                          \"title\": \"Global downturn\",\n                          \"date_range\": \"2025+\",\n                          \"description\": \"Recession conditions persist; ECB maintains rate hikes\"\n                        }\n                      ]\n                    }\n                  ]\n                }\n              ]\n            }\n          ]\n        }\n      ]\n    }\n  ]\n}\n\n[Given Scenario]\nUS large-cap biopharma stocks have underperformed the broader market for two consecutive years, with mixed sentiment shaping investor outlook for 2025. Despite strong fundamentals and advancements in drug pipelines, factors such as political uncertainty and sector rotation have hindered the sector's performance relative to the S&P 500. In 2024, biopharma stocks rose by 9.6%, falling short of the S&P 500's 28.5% surge.\n\nJP Morgan analysts maintain a positive outlook for several key players, including Eli Lilly, Bristol Myers Squibb, Gilead Sciences, and Merck. Obesity is expected to remain a major focus for the industry, with Eli Lilly's orforglipron and tirzepatide in type 2 diabetes being key data catalysts. Bristol Myers Squibb's Cobenfy for schizophrenia is expected to see strong adoption once broader insurance coverage is in place.\n\nSeveral new product launches are on the radar for 2025, including Bristol Myers Squibb's Cobenfy, Gilead Sciences' lenacapavir for pre-exposure prophylaxis, Merck's Winrevair for pulmonary arterial hypertension, and Gilead's Livdelzi for primary biliary cholangitis. JP Morgan expects M&A activity to pick up in 2025, with mid-sized deals around $5-15 billion likely to focus on later-stage, lower-risk assets.\n[Output in JSON]\n",
  "response": "```json\n{\n  \"id\": \"T0\",\n  \"title\": \"Current Situation\",\n  \"description\": \"US large-cap biopharma stocks have underperformed the S&P 500 for two consecutive years, with a 9.6% rise in 2024 compared to the S&P 500's 28.5% surge. Factors include political uncertainty and sector rotation, despite strong fundamentals and advancements in drug pipelines.\",\n  \"children\": [\n    {\n      \"id\": \"T1A1\",\n      \"title\": \"Resolution of Political Uncertainty\",\n      \"date_range\": \"Early 2025\",\n      \"description\": \"Political climate stabilizes with bipartisan support for healthcare initiatives, reducing uncertainty in the biopharma sector.\",\n      \"children\": [\n        {\n          \"id\": \"T1A1.1\",\n          \"title\": \"Enhanced Regulatory Support\",\n          \"date_range\": \"Q1 2025\",\n          \"description\": \"Regulatory agencies like the FDA expedite approvals for key drug candidates, boosting investor confidence.\",\n          \"children\": [\n            {\n              \"id\": \"T2A1.1\",\n              \"title\": \"Accelerated Drug Approvals\",\n              \"date_range\": \"Mid 2025\",\n              \"description\": \"Eli Lilly's orforglipron and tirzepatide receive accelerated approvals for type 2 diabetes, driving stock appreciation.\",\n              \"children\": [\n                {\n                  \"id\": \"T3A1.1\",\n                  \"title\": \"Market Reacts Positively\",\n                  \"date_range\": \"Late 2025\",\n                  \"description\": \"Biopharma stocks surge as investors anticipate increased revenues from new drug launches.\",\n                  \"children\": [\n                    {\n                      \"id\": \"T4A1.1\",\n                      \"title\": \"Increased M&A Activity\",\n                      \"date_range\": \"End 2025\",\n                      \"description\": \"With improved market conditions, major biopharma firms pursue mid-sized companies specializing in obesity and diabetes, leading to deals valued between $5-15 billion.\",\n                      \"children\": [\n                        {\n                          \"id\": \"T5A1.1\",\n                          \"title\": \"Sector Consolidation\",\n                          \"date_range\": \"2026+\",\n                          \"description\": \"Consolidation leads to stronger market leaders, increased R&D investments, and enhanced global market share.\",\n                          \"children\": [\n                            {\n                              \"id\": \"T6A1.1\",\n                              \"title\": \"Long-term Growth Stabilizes\",\n                              \"date_range\": \"2027+\",\n                              \"description\": \"Biopharma sector maintains steady growth, outperforming broader markets with continued innovation and strategic mergers.\"\n                            }\n                          ]\n                        }\n                      ]\n                    }\n                  ]\n                }\n              ]\n            },\n            {\n              \"id\": \"T2A1.2\",\n              \"title\": \"Positive Insurance Coverage Expansion\",\n              \"date_range\": \"Mid 2025\",\n              \"description\": \"Bristol Myers Squibb's Cobenfy gains broader insurance coverage, increasing adoption rates for schizophrenia treatment.\",\n              \"children\": [\n                {\n                  \"id\": \"T3A1.2\",\n                  \"title\": \"Revenue Growth Boost\",\n                  \"date_range\": \"Late 2025\",\n                  \"description\": \"Increased adoption drives higher sales, positively impacting company valuations and investor sentiment.\",\n                  \"children\": [\n                    {\n                      \"id\": \"T4A1.2\",\n                      \"title\": \"Investor Confidence Restored\",\n                      \"date_range\": \"End 2025\",\n                      \"description\": \"Strong revenue projections attract more institutional investments, stabilizing biopharma stock prices.\"\n                    }\n                  ]\n                }\n              ]\n            }\n          ]\n        },\n        {\n          \"id\": \"T1A1.2\",\n          \"title\": \"Sector Rotation Reverses\",\n          \"date_range\": \"Q2 2025\",\n          \"description\": \"Investors rotate back into the biopharma sector from previously favored sectors like technology and energy.\",\n          \"children\": [\n            {\n              \"id\": \"T2A1.3\",\n              \"title\": \"Capital Inflow Increases\",\n              \"date_range\": \"Mid 2025\",\n              \"description\": \"Increased capital inflows drive up biopharma stock valuations, enhancing market liquidity.\",\n              \"children\": [\n                {\n                  \"id\": \"T3A1.3\",\n                  \"title\": \"Enhanced R&D Investments\",\n                  \"date_range\": \"Late 2025\",\n                  \"description\": \"Companies allocate more resources to R&D, accelerating drug pipeline advancements and innovation.\",\n                  \"children\": [\n                    {\n                      \"id\": \"T4A1.3\",\n                      \"title\": \"Breakthrough Therapies\",\n                      \"date_range\": \"2026\",\n                      \"description\": \"New breakthrough therapies emerge from enhanced R&D, further boosting sector growth.\"\n                    }\n                  ]\n                }\n              ]\n            }\n          ]\n        }\n      ]\n    },\n    {\n      \"id\": \"T1A2\",\n      \"title\": \"Persistence of Political Uncertainty\",\n      \"date_range\": \"Early 2025\",\n      \"description\": \"Political gridlock continues with contentious debates over healthcare policies, maintaining uncertainty in the biopharma sector.\",\n      \"children\": [\n        {\n          \"id\": \"T1A2.1\",\n          \"title\": \"Regulatory Delays Continue\",\n          \"date_range\": \"Q1 2025\",\n          \"description\": \"Regulatory agencies face delays in drug approvals due to political pressures, slowing down pipeline advancements.\",\n          \"children\": [\n            {\n              \"id\": \"T2A2.1\",\n              \"title\": \"Slowed Product Launches\",\n              \"date_range\": \"Mid 2025\",\n              \"description\": \"Key drugs like Eli Lilly's tirzepatide experience postponed launches, affecting revenue projections.\",\n              \"children\": [\n                {\n                  \"id\": \"T3A2.1\",\n                  \"title\": \"Investor Sentiment Weakens\",\n                  \"date_range\": \"Late 2025\",\n                  \"description\": \"Continued delays lead to diminished investor confidence, resulting in stagnant or declining stock prices.\",\n                  \"children\": [\n                    {\n                      \"id\": \"T4A2.1\",\n                      \"title\": \"Increased Sector Rotation\",\n                      \"date_range\": \"End 2025\",\n                      \"description\": \"Investors further rotate out of biopharma into less volatile sectors, exacerbating stock underperformance.\",\n                      \"children\": [\n                        {\n                          \"id\": \"T5A2.1\",\n                          \"title\": \"Sector Underperformance Prolongs\",\n                          \"date_range\": \"2026+\",\n                          \"description\": \"Biopharma continues to underperform the broader market, delaying potential recovery and growth.\"\n                        }\n                      ]\n                    }\n                  ]\n                }\n              ]\n            }\n          ]\n        },\n        {\n          \"id\": \"T1A2.2\",\n          \"title\": \"Heightened Regulatory Scrutiny\",\n          \"date_range\": \"Q2 2025\",\n          \"description\": \"Increased political pressure leads to greater regulatory scrutiny on biopharma pricing and approvals.\",\n          \"children\": [\n            {\n              \"id\": \"T2A2.2\",\n              \"title\": \"Pricing Pressures Intensify\",\n              \"date_range\": \"Mid 2025\",\n              \"description\": \"Biopharma companies face pressure to reduce drug prices, impacting profit margins.\",\n              \"children\": [\n                {\n                  \"id\": \"T3A2.2\",\n                  \"title\": \"Cost-Cutting Measures Implemented\",\n                  \"date_range\": \"Late 2025\",\n                  \"description\": \"Companies implement cost-cutting strategies, including workforce reductions and decreased R&D spending.\",\n                  \"children\": [\n                    {\n                      \"id\": \"T4A2.2\",\n                      \"title\": \"Innovation Slows\",\n                      \"date_range\": \"2026\",\n                      \"description\": \"Reduced R&D investments lead to slower innovation and fewer new drug candidates entering the pipeline.\"\n                    }\n                  ]\n                }\n              ]\n            }\n          ]\n        }\n      ]\n    },\n    {\n      \"id\": \"T1A3\",\n      \"title\": \"M&A Activity Picks Up\",\n      \"date_range\": \"Mid 2025\",\n      \"description\": \"JP Morgan analysts predict an increase in M&A activity, focusing on later-stage, lower-risk assets within the biopharma sector.\",\n      \"children\": [\n        {\n          \"id\": \"T1A3.1\",\n          \"title\": \"Strategic Acquisitions\",\n          \"date_range\": \"Late 2025\",\n          \"description\": \"Large-cap biopharma companies acquire mid-sized firms with promising late-stage drug candidates, enhancing their pipelines.\",\n          \"children\": [\n            {\n              \"id\": \"T2A3.1\",\n              \"title\": \"Portfolio Diversification\",\n              \"date_range\": \"Early 2026\",\n              \"description\": \"Acquisitions allow companies to diversify their product portfolios, reducing dependency on single revenue streams.\",\n              \"children\": [\n                {\n                  \"id\": \"T3A3.1\",\n                  \"title\": \"Increased Market Valuations\",\n                  \"date_range\": \"Mid 2026\",\n                  \"description\": \"Diversified portfolios lead to higher market valuations and improved investor sentiment.\",\n                  \"children\": [\n                    {\n                      \"id\": \"T4A3.1\",\n                      \"title\": \"Enhanced Innovation Capacity\",\n                      \"date_range\": \"Late 2026\",\n                      \"description\": \"With increased resources from acquisitions, companies boost their innovation capabilities, leading to more robust drug pipelines.\"\n                    }\n                  ]\n                }\n              ]\n            }\n          ]\n        },\n        {\n          \"id\": \"T1A3.2\",\n          \"title\": \"Synergistic Integrations\",\n          \"date_range\": \"Late 2025\",\n          \"description\": \"Post-acquisition integrations focus on achieving synergies in R&D, manufacturing, and distribution.\",\n          \"children\": [\n            {\n              \"id\": \"T2A3.2\",\n              \"title\": \"Cost Efficiencies Realized\",\n              \"date_range\": \"Early 2026\",\n              \"description\": \"Synergies lead to cost efficiencies, improving profit margins and financial stability.\",\n              \"children\": [\n                {\n                  \"id\": \"T3A3.2\",\n                  \"title\": \"Shareholder Value Increases\",\n                  \"date_range\": \"Mid 2026\",\n                  \"description\": \"Cost efficiencies and expanded pipelines drive up shareholder value, attracting more investments.\"\n                }\n              ]\n            }\n          ]\n        }\n      ]\n    },\n    {\n      \"id\": \"T1A4\",\n      \"title\": \"Successful Product Launches\",\n      \"date_range\": \"Throughout 2025\",\n      \"description\": \"Key biopharma companies launch new products, significantly impacting their market performance.\",\n      \"children\": [\n        {\n          \"id\": \"T1A4.1\",\n          \"title\": \"Bristol Myers Squibb's Cobenfy Adoption\",\n          \"date_range\": \"Q2 2025\",\n          \"description\": \"Cobenfy for schizophrenia sees strong adoption post insurance coverage expansion.\",\n          \"children\": [\n            {\n              \"id\": \"T2A4.1\",\n              \"title\": \"Revenue Surge\",\n              \"date_range\": \"Mid 2025\",\n              \"description\": \"Increased sales from Cobenfy lead to substantial revenue growth for Bristol Myers Squibb.\",\n              \"children\": [\n                {\n                  \"id\": \"T3A4.1\",\n                  \"title\": \"Stock Price Appreciation\",\n                  \"date_range\": \"Late 2025\",\n                  \"description\": \"Positive sales performance drives up Bristol Myers Squibb's stock price.\"\n                }\n              ]\n            }\n          ]\n        },\n        {\n          \"id\": \"T1A4.2\",\n          \"title\": \"Gilead Sciences' Lenacapavir Launch\",\n          \"date_range\": \"Q3 2025\",\n          \"description\": \"Lenacapavir for pre-exposure prophylaxis gains traction in the market.\",\n          \"children\": [\n            {\n              \"id\": \"T2A4.2\",\n              \"title\": \"Market Share Expansion\",\n              \"date_range\": \"Late 2025\",\n              \"description\": \"Lenacapavir captures significant market share, enhancing Gilead Sciences' competitive position.\",\n              \"children\": [\n                {\n                  \"id\": \"T3A4.2\",\n                  \"title\": \"Investor Optimism\",\n                  \"date_range\": \"End 2025\",\n                  \"description\": \"Successful product launch fosters investor optimism, leading to stock price gains.\"\n                }\n              ]\n            }\n          ]\n        },\n        {\n          \"id\": \"T1A4.3\",\n          \"title\": \"Merck's Winrevair Approval\",\n          \"date_range\": \"Q4 2025\",\n          \"description\": \"Winrevair for pulmonary arterial hypertension receives regulatory approval and enters the market.\",\n          \"children\": [\n            {\n              \"id\": \"T2A4.3\",\n              \"title\": \"New Revenue Streams\",\n              \"date_range\": \"Early 2026\",\n              \"description\": \"Winrevair creates new revenue streams, contributing to Merck's financial growth.\",\n              \"children\": [\n                {\n                  \"id\": \"T3A4.3\",\n                  \"title\": \"Enhanced Market Valuation\",\n                  \"date_range\": \"Mid 2026\",\n                  \"description\": \"Merck's diversified product portfolio boosts its market valuation.\"\n                }\n              ]\n            }\n          ]\n        },\n        {\n          \"id\": \"T1A4.4\",\n          \"title\": \"Gilead's Livdelzi Launch\",\n          \"date_range\": \"Late 2025\",\n          \"description\": \"Livdelzi for primary biliary cholangitis enters the market, addressing a niche yet significant patient population.\",\n          \"children\": [\n            {\n              \"id\": \"T2A4.4\",\n              \"title\": \"Niche Market Domination\",\n              \"date_range\": \"Early 2026\",\n              \"description\": \"Livdelzi dominates its niche market, establishing Gilead Sciences as a leader in specialized treatments.\",\n              \"children\": [\n                {\n                  \"id\": \"T3A4.4\",\n                  \"title\": \"Sustained Revenue Growth\",\n                  \"date_range\": \"Mid 2026\",\n                  \"description\": \"Consistent sales from Livdelzi contribute to sustained revenue growth and investor confidence.\"\n                }\n              ]\n            }\n          ]\n        }\n      ]\n    },\n    {\n      \"id\": \"T1A5\",\n      \"title\": \"Mixed Investor Sentiment\",\n      \"date_range\": \"Throughout 2025\",\n      \"description\": \"Despite strong drug pipelines, political uncertainty and sector rotation create a divided investor outlook for biopharma stocks.\",\n      \"children\": [\n        {\n          \"id\": \"T1A5.1\",\n          \"title\": \"Selective Investment Inflows\",\n          \"date_range\": \"Mid 2025\",\n          \"description\": \"Investors selectively invest in biopharma companies with strong pipelines and upcoming catalysts.\",\n          \"children\": [\n            {\n              \"id\": \"T2A5.1\",\n              \"title\": \"Targeted Capital Allocation\",\n              \"date_range\": \"Late 2025\",\n              \"description\": \"Focused investments in companies like Eli Lilly, Bristol Myers Squibb, Gilead Sciences, and Merck drive their performance.\",\n              \"children\": [\n                {\n                  \"id\": \"T3A5.1\",\n                  \"title\": \"Performance Outpaces Underperformers\",\n                  \"date_range\": \"Early 2026\",\n                  \"description\": \"Key biopharma players outperform lesser-positioned peers, garnering market leadership.\",\n                  \"children\": [\n                    {\n                      \"id\": \"T4A5.1\",\n                      \"title\": \"Sector Reputation Rebounds\",\n                      \"date_range\": \"Mid 2026\",\n                      \"description\": \"Successful performances restore the biopharma sector's reputation, attracting broader investment.\"\n                    }\n                  ]\n                }\n              ]\n            }\n          ]\n        },\n        {\n          \"id\": \"T1A5.2\",\n          \"title\": \"Continued Sector Rotation\",\n          \"date_range\": \"Mid 2025\",\n          \"description\": \"Despite selective inflows, broader sector rotation trends continue to limit overall biopharma stock performance.\",\n          \"children\": [\n            {\n              \"id\": \"T2A5.2\",\n              \"title\": \"Gradual Stock Recovery\",\n              \"date_range\": \"Late 2025\",\n              \"description\": \"Underperforming biopharma stocks gradually recover as positive catalysts materialize.\",\n              \"children\": [\n                {\n                  \"id\": \"T3A5.2\",\n                  \"title\": \"Balanced Market Performance\",\n                  \"date_range\": \"Early 2026\",\n                  \"description\": \"Biopharma stocks achieve a balance between underperformance and selective outperformance, aligning closer with the broader market.\"\n                }\n              ]\n            }\n          ]\n        }\n      ]\n    }\n  ]\n}\n```",
  "processing_time": 108.30782294273376,
  "estimated_prompt_tokens": 2175,
  "response_tokens": 3599
}